Literature DB >> 23972814

Management of non-small-cell lung cancer: recent developments.

Martin Reck1, David F Heigener, Tony Mok, Jean-Charles Soria, Klaus F Rabe.   

Abstract

Non-small-cell lung cancer is one of the leading causes of deaths from cancer worldwide. Therefore, improvements in diagnostics and treatments are urgently needed. In this review, we will discuss the evolution of lung cancer staging towards more non-invasive, endoscopy-based, and image-based methods, and the development of stage-adapted treatment. A special focus will be placed on the role of novel surgical approaches and modern radiotherapy strategies for early stages of disease, the effect of multimodal treatment in locally advanced disease, and ongoing developments in the treatment of patients with metastatic disease. In particular, we will include an emphasis on targeted therapies, which are based on the assumption that a treatable driver mutation or gene rearrangement is present within the tumour. Finally, the position of lung cancer treatment on the pathway to personalised therapy will be discussed.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23972814     DOI: 10.1016/S0140-6736(13)61502-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  312 in total

1.  Video-assisted thoracoscopic lobectomy with a single utility port is feasible in the treatment of elderly patients with peripheral lung cancer.

Authors:  Chang Li; Chun Xu; Haitao Ma; Bin Ni; Jun Chen; Tengfei Chen; Hongtao Zhang; Jun Zhao
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

2.  Human papillomavirus capsids preferentially bind and infect tumor cells.

Authors:  Rhonda C Kines; Rebecca J Cerio; Jeffrey N Roberts; Cynthia D Thompson; Elisabet de Los Pinos; Douglas R Lowy; John T Schiller
Journal:  Int J Cancer       Date:  2015-10-27       Impact factor: 7.396

3.  Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Authors:  Wolfgang A Weber; Constantine A Gatsonis; P David Mozley; Lucy G Hanna; Anthony F Shields; Denise R Aberle; Ramaswamy Govindan; Drew A Torigian; Joel S Karp; Jian Q Michael Yu; Rathan M Subramaniam; Robert A Halvorsen; Barry A Siegel
Journal:  J Nucl Med       Date:  2015-04-23       Impact factor: 10.057

4.  Video-assisted thoracoscopic surgery for non-small-cell lung cancer in elderly patients: a single-center, case-matched study.

Authors:  Keqiang Liu; Jing Zhao; Weiqiang Zhang; Jian Tan; Jingbo Ma; Yingxin Pei
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.

Authors:  Han Zhao; Yu-Zhuo Xie; Rui Xing; Ming Sun; Feng Chi; Yue-Can Zeng
Journal:  Cell Oncol (Dordr)       Date:  2017-05-31       Impact factor: 6.730

Review 6.  Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer.

Authors:  Meng-Feng Tsai; Chi-Chung Wang; Jeremy Jw Chen
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.

Authors:  Claudia Stumpf; Daniel Kaemmerer; Elisa Neubauer; Jörg Sänger; Stefan Schulz; Amelie Lupp
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

8.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

Review 9.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08

10.  Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer.

Authors:  Huanxian Chen; Linmin Chen; Liang Wang; Xinhua Zhou; Judy Yuet-Wa Chan; Jingjing Li; Guozhen Cui; Simon Ming-Yuen Lee
Journal:  Cancer Biol Ther       Date:  2016-09-15       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.